Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

June 14, 2024

https://www.globenewswire.com/news-release/2024/06/14/2898928/0/en/Cogent-Biosciences-Announces-Additional-Clinical-Data-from-Part-1-of-its-Ongoing-SUMMIT-Trial-Evaluating-Bezuclastinib-in-Patients-with-NonAdvanced-Systemic-Mastocytosis-NonAdvSM.html

Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions

Reductions were shown in all individual MS2D2 symptoms across domains and objective reduction in skin lesions corresponding with symptomatic improvement

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.